Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
NCT ID: NCT06794996
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
45 participants
INTERVENTIONAL
2025-02-04
2026-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IXP (Inaxaplin)
Participants with proteinuric APOL1-mediated kidney disease (AMKD) with or without the comorbidity of Type 2 diabetes mellitus (T2DM) will receive a single dose of IXP once daily, for 13 weeks.
Inaxaplin
Tablets for Oral Administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inaxaplin
Tablets for Oral Administration.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Estimated Glomerular Filtration Rate (eGFR) of greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73m\^2 at screening
Exclusion Criteria
* Uncontrolled hypertension
18 Years
67 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vertex Pharmaceuticals Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nephrology Consultants, LLC
Huntsville, Alabama, United States
Foundation for Sickle Cell Disease Research, LLC
Hollywood, Florida, United States
South Florida Research Institute
Lauderdale Lakes, Florida, United States
Schiff Center for Liver Diseases
Miami, Florida, United States
CTR Oakwater, LLC
Orlando, Florida, United States
Renal Associates, LLC
Columbus, Georgia, United States
Georgia Nephrology - Decatur
Decatur, Georgia, United States
Javara Inc./Privia Medical Group Georgia, LLC - Fayetteville
Fayetteville, Georgia, United States
Georgia Nephrology
Lawrenceville, Georgia, United States
Javara Inc. /Privia Medical Group Georgia, LLC - Savannah
Savannah, Georgia, United States
Renal Associates of Baton Rouge
Baton Rouge, Louisiana, United States
LCMC Health
Metairie, Louisiana, United States
Ochsner Medical Center - New Orleans - Nephrology
New Orleans, Louisiana, United States
Northwest Louisiana Nephrology, LLC - Shreveport
Shreveport, Louisiana, United States
Javara Inc./Privia Medical Group, LLC MidAtlantic-Silver Spring, MD
Silver Spring, Maryland, United States
Nephrology Associates, P.C.
Columbus, Mississippi, United States
Nephrology and Hypertension Associates, LTD
Tupelo, Mississippi, United States
DaVita Clinical Research
Las Vegas, Nevada, United States
Saint Michael's Medical Center - Peter Ho Memorial Clinic
Newark, New Jersey, United States
Rutgers Doctors Office Center
Newark, New Jersey, United States
Scott Research, Inc.
Laurelton, New York, United States
NYC Health + Hospital/Harlem
New York, New York, United States
North Carolina Nephrology P.A. - Cary Office
Cary, North Carolina, United States
UNC Clinical and Translational Research Center
Chapel Hill, North Carolina, United States
Duke University Hospital - Children's Health Center
Durham, North Carolina, United States
Eastern Nephrology Associates - New Bern Office
New Bern, North Carolina, United States
Lewis Katz School of Medicine at Temple University - Section of Nephrology
Philadelphia, Pennsylvania, United States
Columbia Nephrology Associates, PA
Columbia, South Carolina, United States
Carolina Nephrology, PA
Spartanburg, South Carolina, United States
Dallas Renal Group - 2
Dallas, Texas, United States
Dallas Renal Group - 1
Dallas, Texas, United States
Dallas Nephrology Associates - Dallas Landry Office
Dallas, Texas, United States
UTSW Medical Center - Nephrology
Dallas, Texas, United States
Prolato Clinical Research Center
Houston, Texas, United States
Tks Research, P.L.L.C.
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VX24-147-202
Identifier Type: -
Identifier Source: org_study_id